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Abstract
Background: Metastases to the breast occur rarely, but may be increasing in incidence as patients
live longer with malignant diseases. The aim of this study is to characterize metastatic disease to
the breast and to describe the management and prognosis of patients who present with this
diagnosis.
Methods: A retrospective review of our institution's pathology and breast cancer databases was
performed in order to identify patients with breast malignancies that were not of primary breast
origin. Chart review provided additional information about the patients' primary malignancies and
course of illness.
Results: Between 1991 and 2006, eighteen patients with metastatic disease to the breast of nonhematologic origin were identified and all had charts available for review. Among the 18 patients
with disease metastatic to the breast, tissues of origin included 3 ovarian, 6 melanoma, 3 medullary
thyroid, 3 pulmonary neuroendocrine, 1 pulmonary small cell, 1 oral squamous cell, and 1 renal cell.
Overall mean survival after diagnosis of metastatic disease to the breast was 22.4 months.
Treatment of metastases varied and included combinations of observation, surgery, radiation, and
chemotherapy. Five patients (27.8%) required a change in management of their breast disease for
local control.
Conclusion: Due to the variable course of patients with metastatic disease, a multi-disciplinary
approach is necessary for each patient with disease metastatic to the breast to determine optimal
treatment. Based on our review, many patients survive for long periods of time and local treatment
of metastases to the breast may be beneficial in these patients to prevent local complications.
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Background
Metastatic disease to the breast occurs rarely, but may
become an increasingly frequent diagnosis as patients
continue to live longer with malignant diseases. Breast
carcinoma continues to be the most common malignancy
in women in the United States and constitutes approximately 30% of all female malignancies. Metastatic neoplasms to the breast account for 0.5–6.6% of all
malignant mammary tumors and, like primary breast cancer, occur more frequently in women. Metastatic lesions
to the breast tend to be painless discrete masses and are
commonly associated with axillary adenopathy [1]. As a
result, diagnostic dilemmas often arise in differentiating
these rare neoplasms metastatic to the breast from the significantly more common primary breast carcinomas.
Series with the highest rates of metastatic disease to the
breast are due to the inclusion of systemic malignancies,
including both lymphomas and leukemias [1,2]. Very little is known about the prognosis or treatment of patients
with non-hematologic metastases to the breast. The current study aims to investigate our institutional series of
patients with these rare malignancies in order to identify
methods of management and overall prognosis.

Methods
An Institutional Review Board protocol was approved to
retrospectively review the surgical oncology and pathology databases at Washington University School of Medicine from January 1, 1991 through December 31, 2006 in
order to identify patients with neoplasms metastatic to the
breast. After identifying potential patients, pathology
reports and medical charts were reviewed to identify those
patients who had documented elsewhere primaries with
pathologically identified metastases to the breast. Patients
with systemic malignancies, including lymphomas and
leukemias, were excluded. Patients whose primary malignancy could not be conclusively identified were excluded.
Eighteen patients were identified fulfilling these criteria,
and their medical records were extensively reviewed. Data
collected included patient demographics and details of
their primary malignancies and treatment courses. Information regarding the detection, pathology, and treatment
of the secondary breast neoplasm was also recorded.
Descriptive statistics were utilized for data presentation.

Results
Eighteen patients were identified with primary malignancies metastatic to the breast between 1991 and 2006
(Table 1). These patients represented 0.2% of the total
number of patients treated for breast malignancies during
the study period. Six patients had malignant melanoma, 3
had medullary thyroid carcinoma, 3 had ovarian carcinoma, 3 had pulmonary neuroendocrine carcinoma, 1
had small cell carcinoma of the lung, 1 had squamous cell
carcinoma of the tongue, and 1 had renal cell carcinoma.

http://www.wjso.com/content/5/1/74

When reviewing all 18 patients, the average time between
initial diagnosis of the primary malignancy and development of a metastasis to the breast was 60.9 months (range
0–276 months). Mean length of survival after being diagnosed with disease metastatic to the breast was 22.4
months (range 5–120 months). Six of the 18 patients
were alive at follow-up with an average of 31.5 months
having elapsed since being diagnosed with a breast metastasis. Of the 12 patients who have died of their diseases,
the mean survival time after developing a breast metastasis was 17.8 months (range 5–37 months).
The method of diagnosis and the patients' treatments varied considerably, as did their disease courses (Table 2).
Twelve of the patients had routine breast imaging performed, including mammograms and/or ultrasounds.
Examples of representative mammogram and ultrasound
images from one of our patients are shown in Figures 1, 2,
3, 4. Seven patients had a breast core needle biopsy performed for diagnostic purposes without further surgical
excision; all 7 patients had widespread metastatic disease.
Eleven patients underwent surgical excision of the metastatic breast lesion, though the indications and control of
the underlying primary disease varied widely. Four
patients had an isolated breast metastasis and underwent
complete surgical excision of the breast metastasis for curative intent. Five patients had either a partial mastectomy
or an excisional biopsy of the metastatic breast lesion; all
5 patients had widespread metastatic disease and the reasons for excision were unclear from the retrospective
review. One patient with metastatic ovarian cancer
required mastectomy for local control of a rapidly enlarging tumor. One patient had an excisional biopsy to differentiate between primary breast carcinoma and metastatic
medullary thyroid carcinoma.
A change in management occurred in 5 of the 18 patients
(27.8%) due to local breast complications. One patient
with ovarian cancer metastatic to the breast was initially
managed conservatively after a core needle biopsy was
performed for diagnosis, but subsequently required mastectomy due to large tumor burden and local wound complications. One patient required an additional excisional
biopsy when a metastatic melanoma recurred in the
breast. A second patient with malignant melanoma metastatic to the breast had a local recurrence after partial mastectomy and required simple mastectomy for treatment.
One patient with metastatic pulmonary neuroendocrine
carcinoma required radiation treatment to the breast after
a breast metastasis recurred following excisional biopsy.
One male patient with metastatic renal cell carcinoma was
being observed after a core needle biopsy diagnosed a
breast metastasis. The mass enlarged and became tender
and was then treated with radiation therapy resulting in
local control with a decrease in size of the mass.

Page 2 of 8
(page number not for citation purposes)

World Journal of Surgical Oncology 2007, 5:74

http://www.wjso.com/content/5/1/74

Table 1: Characteristics of patients with metastatic disease to the breast

Primary
malignancy

Melanoma
Melanoma
Melanoma
Melanoma
Melanoma
Melanoma
Thyroid
Thyroid
Thyroid
Ovarian
Ovarian
Ovarian
Lung (small cell)
Lung (neuroendocrine)
Lung (neuroendocrine)
Lung (neuroendocrine)
Tongue
Kidney

Age at
Diagnosis
(years)*

Time to
metastasis
(months)**

Vital Status

Secondary
Survival
(months)***

Breast
Laterality

Breast Surgical
Treatment

26
23
59
83
70
38
13
17
29
59
63
49
83
30
35
28
48
67

48
276
34
9
36
66
264
144
14
84
14
3
0
38
0
8
10
48

Dead
Dead
Dead
Dead
Dead
Dead
Dead
Alive with disease
Alive with disease
Dead
Alive with disease
Dead
Alive with disease
Alive with disease
Alive with disease
Dead
Dead
Dead

5
6
9
24
36
38
16
18
120
6
14
37
21
7
9
17
8
12

Left
Right
Left
Right
Right
Left
Left
Left
Bilateral
Right
Right
Right
Right
Left
Bilateral
Right
Right
Left

Excision
Biopsy only
Biopsy only
Mastectomy
Excision, ALND
MRM
Excision
Biopsy only
Excision
Excisional biopsy
MRM
Excisional biopsy
Biopsy only
Excision
Biopsy only
Excision
Biopsy only
Biopsy only

ALND = axillary lymph node dissection; MRM = modified radical mastectomy
*Age at diagnosis of primary malignancy
** Time between primary malignancy diagnosis and the development of a breast metastasis
***Survival after the diagnosis of a breast metastasis until death or study follow-up.

Patient treatment varied according to the type of primary
malignancy diagnosed. Six patients had malignant
melanoma. The mean time between diagnosis of
melanoma and development of a breast metastasis was
78.2 months (range 9–276 months). The mean survival
after the diagnosis of a metastasis to the breast was 19.7
months (range 5–38 months). All presented with palpable breast masses. Two patients had core biopsies for diagnosis and no further local treatment to the breast, and
neither of them developed local breast complications
prior to their deaths. Four of the 6 patients with
melanoma underwent resection of the secondary breast
malignancy. One patient had a partial mastectomy with
negative surgical margins; she succumbed to her metastatic disease 5 months later without evidence of local
breast recurrence. One had an excisional biopsy for diagnosis followed by an ipsilateral axillary node dissection
but developed a locoregional recurrence in the breast at
20 months post-excision, requiring a subsequent excisional biopsy; there was no evidence of breast recurrence
at the time of death. One patient had an excisional biopsy
with frozen section evaluation at the time of resection of
a primary site local recurrence. Intraoperative pathology
confirmed metastatic malignant melanoma and partial
mastectomy with negative margins was performed at that
time. She subsequently developed a recurrence in both
her primary site and breast. At that time she had wide
local excision of her primary recurrence as well as simple
mastectomy for her breast recurrence. She died of progres-

sive metastatic disease more than 18 months after mastectomy. One patient underwent modified radical
mastectomy after an excisional biopsy diagnosed the
breast metastasis and was free of a breast recurrence at the
time of her death.
Three patients had medullary thyroid carcinoma metastatic to the breast, and all 3 had MEN syndrome. The
mean time between diagnosis of their thyroid malignancies and development of a breast metastasis was 140.7
months (range 14–264 months). The mean survival after
diagnosis of the breast metastasis was 51 months (range
16–120 months). All presented with palpable masses.
One patient had a core needle biopsy only and no additional local treatment and died of the primary malignancy
18 months later with the breast metastasis intact. One
patient had an excisional biopsy and died of the primary
malignancy 16 months later without evidence of breast
recurrence. One patient had two excisional biopsies of
breast metastases and is alive at follow-up, but has suffered an additional locoregional recurrence in the breast;
no further local therapy is planned.
Three patients with ovarian carcinoma presented with
metastases to the breast. The mean time between diagnosis of ovarian carcinoma and development of a breast
metastasis was 33.7 months (range 3–84 months). The
mean survival after development of the breast metastasis
was 19 months (range 6–37 months). One patient had a
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Table 2: Treatment and outcome of metastases to the breast

Primary malignancy

Breast
Imaging

BI-RADS
category

Other
metastases

Diagnostic
Modality

Breast Surgical
Treatment

Excision
margins

Local
recurrence

Melanoma
Melanoma
Thyroid
Lung (small cell)
Lung (neuroendocrine)
Tongue
Kidney
Melanoma
Melanoma
Melanoma
Melanoma
Thyroid
Thyroid
Ovarian
Ovarian
Ovarian
Lung (neuroendocrine)
Lung (neuroendocrine)

MMG, U/S
MMG, U/S
MMG
MMG, U/S
MMG, U/S
MMG
None
MMG, U/S
None
None
None
MMG, U/S
MMG, U/S
None
MMG, U/S
MMG, U/S
MMG, U/S
None

4
5
4
5
4
5
N/A
4
N/A
N/A
N/A
6
3
N/A
4
4
4
N/A

Widespread
Widespread
Widespread
Widespread
Widespread
Widespread
Widespread
Locoregional
No
No
Widespread
Widespread
Widespread
Widespread
Widespread
No
Widespread
Widespread

CNB
CNB
CNB
CNB
CNB
CNB
CNB
Excision
Excision
Excision
FNA
Excision
Excision
Excision
CNB
Excision
CNB
Excision

None
None
None
None
None
None
None
Excision
Excision, ALND
MRM
Excision
Excision
Excision
Excision
MRM
Excision
Excision
Excision

N/A
N/A
N/A
N/A
N/A
N/A
N/A
Negative
Negative
Negative
Negative
Negative
Negative
Positive
Negative
Negative
Positive
Negative

N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
Yes
No
No
Yes
No
No
No
No
No
Yes

BI-RADS = Breast Imaging Reporting and Data System; MMG = mammogram; U/S = ultrasound; N/A = not available and/or applicable; FNA = fine
needle aspiration biopsy; CNB = core needle biopsy; ALND = axillary lymph node dissection; MRM = modified radical mastectomy

core needle biopsy for diagnosis with no initial plans for
further local therapy due to her widely metastatic ovarian
disease. She subsequently developed progressive enlargement of the breast metastasis necessitating a palliative
modified radical mastectomy for local control. Two
patients underwent excisional biopsy with negative margins and were free of breast recurrence at the time of
death.

Three patients had pulmonary neuroendocrine carcinoma. One patient presented with a breast metastasis 38
months after her original diagnosis. She subsequently
underwent a partial mastectomy and is still living 7
months later with no evidence of breast disease. The second patient presented with bilateral breast masses and
was initially thought to have bilateral invasive ductal cancer after bilateral core needle biopsies. Further review of
pathology identified an immunohistochemical profile

masses
Left
year-old
Figure
and1right
patient
craniocaudal
who presented
mammogram
with bilateral
viewspalpable
from a breast
35
Left and right craniocaudal mammogram views from a 35
year-old patient who presented with bilateral palpable breast
masses. She was found to have metastatic disease to her
breast from a lung neuroendocrine carcinoma.

Figure
patient
Left andwho
2rightpresented
mediolateral
withoblique
bilateralviews
palpable
frombreast
a 35 year-old
masses
Left and right mediolateral oblique views from a 35 year-old
patient who presented with bilateral palpable breast masses.
She was found to have metastatic disease to her breast from
a lung neuroendocrine carcinoma.
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Figure
Right
eral
palpable
breast
3 ultrasound
breast masses
from a 35 year-old patient with bilatRight breast ultrasound from a 35 year-old patient with bilateral palpable breast masses. The ultrasound documented a
19 × 14 mm hypoechoic mass. She was found to have metastatic disease to her breast from a lung neuroendocrine carcinoma.
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Figure
Left
eral
palpable
breast
4 ultrasound
breast masses
from a 35 year-old patient with bilatLeft breast ultrasound from a 35 year-old patient with bilateral palpable breast masses. The ultrasound documented a
42 × 36 mm hypoechoic mass. She was found to have metastatic disease to her breast from a lung neuroendocrine carcinoma.

her disease 8 months after developing the breast metastasis.
consistent with a neuroendocrine carcinoma and subsequently a lung primary, as well as diffuse visceral metastases, were identified. Figures 5, 6, 7 show her diagnostic
breast core needle biopsy histology. This patient has had
no surgical treatment of her breast metastases and is currently living with stable breast disease 9 months later. The
third patient developed the breast metastasis 8 months
after her original diagnosis and underwent an excisional
biopsy. She developed another breast metastasis 4
months after the first was excised, and this lesion was
treated with radiation therapy and no additional surgery.
She died of her disease 17 months after developing her
initial breast metastasis.
One patient had pulmonary small cell carcinoma, with a
breast mass as the first presenting symptom. Pathological
analysis of a core needle biopsy revealed a small cell carcinoma and staging studies identified a lung primary. She
has had no further local breast treatment and is living 21
months later with widely metastatic disease.
One patient initially presented with a squamous cell carcinoma of the tongue. She developed a palpable breast
mass 10 months later and had a core needle biopsy performed confirming metastatic squamous cell carcinoma.
She had diffuse nodal and visceral metastases and died of

One patient had a renal cell carcinoma. This is the only
male patient identified in our review, and he developed
his breast metastasis 48 months after his original diagnosis. He had a core needle biopsy for diagnosis followed by
radiation treatment to his breast metastasis. He had multiple pulmonary metastases, as well, and died of his disease 12 months after developing the breast metastasis.

Discussion
Metastatic disease to the breast continues to be a rare
manifestation of primary non-hematologic malignancies.
It is predominantly a disease of women, similar to that
observed with primary breast cancers. As systemic treatment for patients with metastatic malignancies becomes
more efficacious and overall survival improves, the emergence of secondary breast neoplasms is also likely to
increase in number. The majority of information on this
topic in the literature consists of case reports and small
case series [1-9]. The inability to predict either an individual patient's longevity or whether a patient will develop
local complications of his or her metastatic disease makes
treatment decision-making difficult. There is minimal
information in the literature regarding prognosis of
patients with disease metastatic to the breast [1]. For our
group of patients, the mean survival time after being diagnosed with a breast metastasis was 22.4 months. Mean
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Figure 5breast
Histological
palpable
sections
masses
from a 35 year-old patient with bilateral
Histological sections from a 35 year-old patient with bilateral
palpable breast masses. A representative hematoxylin and
eosin section of the left breast mass core needle biopsy specimen is shown at 600 × magnification. The tumor is composed of diffuse sheets of small polygonal cells with nuclear
molding, scant cytoplasm, brisk apoptotic rate, and numerous
mitoses. Tumor cells were negative for estrogen receptor,
progesterone receptor, and Her2neu (slides not shown).

survival following development of a breast metastasis was
similar for most of our patients regardless of their primary
tumor origin, except for patients with a primary medullary
thyroid cancer who had a prolonged mean survival (51
months).
The clinical and mammographic features of secondary
breast neoplasms have been described [2,10,11]. The
lesions are typically mobile, well demarcated, firm, but
they lack microcalcifications or skin changes that are often
associated with primary breast carcinomas [10,11]. They
can be confused radiologically for benign breast disease
due to their often well-circumscribed nature and/or presence of bilateral or multiple lesions. The difficulty in interpreting these imaging characteristics were evident in our
patients, as only 3 of the 18 patients had a BI-RADS category 5 designation. Thus, a detailed personal history of
malignancy is vital information for the mammographer in
order to fully evaluate breast lesions arising in patients
with prior or current malignancies of any type.
Two of our patients developed breast masses as their first
indication of a primary malignancy. Interestingly, both
patients had a pulmonary malignancy as their primary
tumors (1 small cell and 1 neuroendocrine). Toombs and
Kalisher [1] published a report on 12 patients with small
cell lung carcinoma who developed breast metastases. Six
of their patients had a palpable breast mass as the initial

http://www.wjso.com/content/5/1/74

nostaining
Sections
shown
Figure
in6ofFigure
the left
5 were
breast
positive
mass core
for chromogranin
needle biopsy A
specimen
immuSections of the left breast mass core needle biopsy specimen
shown in Figure 5 were positive for chromogranin A immunostaining.

presenting sign/symptom. The overall survival in their
study was 17.8 months, which was significantly longer
than previously published reports, likely reflecting
improvements in systemic treatment that had occurred in
the 30 years previous to their report. Significant improvements in systemic therapy are likely to continue to
lengthen overall survival, as evidenced by our patient with
small cell lung carcinoma and a breast metastasis who is
currently alive at follow-up (21 months).
The treatment of patients with these metastatic breast
lesions varied widely in our study. While the majority of
our patients did undergo some type of formal resection of
their breast metastases (11 of 18 overall, 61%), only 4
patients (22%) had a resection for curative intent. In addition, 5 of the 18 patients (27.8%) required a change in
their initial management due to the secondary breast
malignancy. Why some of our patients with secondary
breast neoplasms were offered surgical excision of the
tumor in the face of widely metastatic disease, while others were not, is unclear. Perhaps patients who have a better initial prognosis, as subjectively evaluated by the
physician (low tumor burden, clearance of metastases
with adjuvant therapy, minimal comorbidities, younger
age), were more likely to be given the option of surgery.
We know very little about the complex physician and
patient treatment decision-making processes for patients
with secondary breast neoplasms, and we cannot infer a
causal relationship based on this retrospective study.
One theory for the use of surgical excision of a breast
metastasis may be related to the primary tumor biology
and the extent of metastatic disease. Physicians may be
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ous types of metastatic cancers and may not be generalizable across types.

taining in7of
Sections
shown
Figure
Figure
the left
5 were
breastpositive
mass core
for synaptophysin
needle biopsy immunosspecimen
Sections of the left breast mass core needle biopsy specimen
shown in Figure 5 were positive for synaptophysin immunostaining. Identical histological features were seen on the contralateral breast core biopsy specimen. The immunostain
results suggested a neuroendocrine carcinoma, rather than a
primary breast adenocarcinoma. Staging exams confirmed a
lung primary.

more inclined to recommend resection of a breast metastasis for patients with indolent primary tumors, patients
with an isolated metastasis, or patients with primary
tumors to which adjuvant systemic and radiation therapies have little effect. Patients with metastatic melanoma
or medullary thyroid cancer often undergo metastasectomy, as shown in previous reports [12,13] and in the current study. For patients with widely metastatic cancer,
surgical debulking may play a part in the treatment of
these patients. The association between a decrease in
tumor burden and improvement in survival is observed in
several aggressive metastatic cancers, such as ovarian,
renal, colorectal, and gastric cancers, which are managed
with surgical debulking before the receipt of adjuvant systemic chemotherapy [14-24]. Surgical debulking can help
restore the patient's immune system, improve their nutritional status, decrease the seeding of metastases, and
increase the efficacy of adjuvant treatment [15]. A lower
tumor burden makes chemotherapy more effective and
can limit the emergence of chemoresistant cell lines [18].
Surgery also removes necrotic tumor areas that may be
inaccessible to drugs [15]. However, one must use caution
in applying these theories across varying carcinomas. In
the case of colorectal and gastric cancer, this benefit is
negated by incomplete metastasectomy [20-24]. In addition, the impact of tumor-specific biological factors, such
as route of metastatic spread, responsiveness to systemic
therapies, and growth kinetics differ widely among vari-

Another factor that could contribute to the use of surgical
excision of a secondary breast neoplasm is the disease-free
interval between diagnosis of the primary tumor and
emergence of the breast metastasis. This has been well
studied in the colorectal literature, and patients with synchronous or metachronous liver metastases have a poorer
overall survival following liver metastasectomy compared
to patients who develop a liver metastasis years after their
initial colorectal cancer diagnosis [21-23]. Georgiannos et
al. [8] demonstrated an average time between the primary
malignancy diagnosis and the development of a breast
metastasis of 2 years. This is significantly shorter than in
the current study where the average was greater than 5
years. We attribute this to the fact that we excluded hematologic malignancies, whereas the former study did not.
Finally, surgical excision of metastatic disease to the breast
may be performed for purely palliative indications. This
line of reasoning parallels the surgical treatment approach
for patients with metastatic primary breast cancer. Historically, surgical treatment for metastatic (stage IV) primary
breast cancer has been reserved only for cases when the
primary tumor has led to complications, such as skin
ulceration, infection with foul drainage, and life-threatening bleeding [25]. Improvements in systemic therapies for
the various primary tumors in our study population may
result in longer life expectancies and increased risk of local
wound complications from the metastases to the breast.
The relatively low morbidity and mortality associated
with surgical resections for breast malignancies (in contrast to surgical debulking for ovarian, colon, gastric, and
renal cell cancers) may result in a higher likelihood that
surgical resection is recommended in patients with incurable metastatic disease.
The results of this single-institution study must be interpreted in light of its limitations. Limitations of our study
include its retrospective analysis approach, the limited
number of patients precluding quantitative statistical
analysis, and the variability in types and methods of local
and systemic therapies utilized. Another limitation of our
study was the heterogeneity of our patient population.
Wide variations in tumor origin, metastatic burden, and
characteristics of the breast tumor metastases exist in the
patient population.

Conclusion
While systemic therapy remains the cornerstone for metastatic malignancies, locoregional control of disease metastatic to the breast may play a vital role in select patients.
As patients continue to live longer with malignant disease,
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individualized, multidisciplinary consideration must be
given to the use of surgery to control local breast disease.
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